Abstract
A minority of normal subjects have an impaired ability to oxidise sulphur, which is associated with an increased risk of side effects when they receive sulphur containing drugs. In 114 patients with rheumatoid arthritis a greatly increased prevalence of poor sulphoxidation was found in 82 (72%) patients compared with 70/200 (35%) healthy controls, 45/121 (37%) controls matched for age, and 4/35 (11%) of the normal aged general population. In a longitudinal study of 37 patients there was no significant alteration in sulphoxidation status after the introduction of a second line drug or with marked changes in the acute phase response. It seems, therefore, that the poor sulphoxidation status in patients with RA is not an epiphenomenon and may be an important factor in determining the clinical features of rheumatoid disease.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bradley H., Waring R. H., Emery P., Arthur V. Metabolism of low-dose paracetamol in patients with rheumatoid arthritis. Xenobiotica. 1991 May;21(5):689–693. doi: 10.3109/00498259109039509. [DOI] [PubMed] [Google Scholar]
- Carroll G. Measurement of sulphated glycosaminoglycans and proteoglycan fragments in arthritic synovial fluid. Ann Rheum Dis. 1989 Jan;48(1):17–24. doi: 10.1136/ard.48.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Emery P., Panayi G. S., Huston G., Welsh K. I., Mitchell S. C., Shah R. R., Idle J. R., Smith R. L., Waring R. H. D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J Rheumatol. 1984 Oct;11(5):626–632. [PubMed] [Google Scholar]
- Hall N. C., Gillan A. H. Effects of antirheumatic drugs on protein sulphydryl reactivity of human serum. J Pharm Pharmacol. 1979 Oct;31(10):676–680. doi: 10.1111/j.2042-7158.1979.tb13627.x. [DOI] [PubMed] [Google Scholar]
- Küpfer A., Idle J. R. False positives with current carbocisteine protocol for sulphoxidation phenotyping. Lancet. 1990 May 5;335(8697):1107–1107. doi: 10.1016/0140-6736(90)92688-e. [DOI] [PubMed] [Google Scholar]
- Madhok R., Capell H. A., Waring R. Does sulphoxidation state predict gold toxicity in rheumatoid arthritis? Br Med J (Clin Res Ed) 1987 Feb 21;294(6570):483–483. doi: 10.1136/bmj.294.6570.483. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mitchell S. C., Waring R. H., Haley C. S., Idle J. R., Smith R. L. Genetic aspects of the polymodally distributed sulphoxidation of S-carboxymethyl-L-cysteine in man. Br J Clin Pharmacol. 1984 Oct;18(4):507–521. doi: 10.1111/j.1365-2125.1984.tb02498.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mitchell S. C., Waring R. H. The deficiency of sulfoxidation of S-carboxymethyl-L-cysteine. Pharmacol Ther. 1989;43(2):237–249. doi: 10.1016/0163-7258(89)90120-4. [DOI] [PubMed] [Google Scholar]
- Olomu A. B., Vickers C. R., Waring R. H., Clements D., Babbs C., Warnes T. W., Elias E. High incidence of poor sulfoxidation in patients with primary biliary cirrhosis. N Engl J Med. 1988 Apr 28;318(17):1089–1092. doi: 10.1056/NEJM198804283181703. [DOI] [PubMed] [Google Scholar]
- Scadding G. K., Ayesh R., Brostoff J., Mitchell S. C., Waring R. H., Smith R. L. Poor sulphoxidation ability in patients with food sensitivity. BMJ. 1988 Jul 9;297(6641):105–107. doi: 10.1136/bmj.297.6641.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Steventon G., Williams A. C., Waring R. H., Pall H. S., Adams D. Xenobiotic metabolism in motor neuron disease. Lancet. 1988 Sep 17;2(8612):644–647. doi: 10.1016/s0140-6736(88)90467-9. [DOI] [PubMed] [Google Scholar]
- Waring R. H. Pharmacogenetics of the S-oxidation of S-carboxymethyl-L-cysteine. Drug Metabol Drug Interact. 1988;6(3-4):253–263. doi: 10.1515/dmdi.1988.6.3-4.253. [DOI] [PubMed] [Google Scholar]